company background image
002007 logo

Hualan Biological Engineering SZSE:002007 Stock Report

Last Price

CN¥15.64

Market Cap

CN¥29.3b

7D

-4.5%

1Y

-31.7%

Updated

30 Jul, 2024

Data

Company Financials +

Hualan Biological Engineering Inc.

SZSE:002007 Stock Report

Market Cap: CN¥29.3b

002007 Stock Overview

A biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China.

002007 fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance4/6
Financial Health5/6
Dividends3/6

Hualan Biological Engineering Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hualan Biological Engineering
Historical stock prices
Current Share PriceCN¥15.64
52 Week HighCN¥24.55
52 Week LowCN¥14.86
Beta0.25
11 Month Change-0.95%
3 Month Change-19.67%
1 Year Change-31.67%
33 Year Change-59.89%
5 Year Change-31.26%
Change since IPO1,415.88%

Recent News & Updates

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09
Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07
These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Recent updates

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09
Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07
These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27
Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Shareholder Returns

002007CN BiotechsCN Market
7D-4.5%-6.8%-3.0%
1Y-31.7%-27.9%-21.8%

Return vs Industry: 002007 underperformed the CN Biotechs industry which returned -27.9% over the past year.

Return vs Market: 002007 underperformed the CN Market which returned -21.8% over the past year.

Price Volatility

Is 002007's price volatile compared to industry and market?
002007 volatility
002007 Average Weekly Movement4.0%
Biotechs Industry Average Movement5.8%
Market Average Movement5.7%
10% most volatile stocks in CN Market9.0%
10% least volatile stocks in CN Market3.8%

Stable Share Price: 002007's share price has been volatile over the past 3 months.

Volatility Over Time: 002007's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19923,709Bei Fanwww.hualanbio.com

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company’s vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine.

Hualan Biological Engineering Inc. Fundamentals Summary

How do Hualan Biological Engineering's earnings and revenue compare to its market cap?
002007 fundamental statistics
Market capCN¥29.26b
Earnings (TTM)CN¥1.39b
Revenue (TTM)CN¥5.25b

20.6x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002007 income statement (TTM)
RevenueCN¥5.25b
Cost of RevenueCN¥1.75b
Gross ProfitCN¥3.50b
Other ExpensesCN¥2.11b
EarningsCN¥1.39b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 30, 2024

Earnings per share (EPS)0.76
Gross Margin66.65%
Net Profit Margin26.52%
Debt/Equity Ratio8.0%

How did 002007 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

39%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.